The E3 Ligase FBXO38 Controls PD-1 Expression and Antitumor Immunity

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-213
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

PD-1 Antitumor Immunity Against Murine H22 Hepatocarcinoma in Vivo

International Journal of Sciences
2018English

Differential Control of CD28-Regulated in Vivo Immunity by the E3 Ligase CBL-B

Journal of Immunology
AllergyImmunology
2005English

Immune Suppression by PD-L2 Against Spontaneous and Treatment-Related Antitumor Immunity

Clinical Cancer Research
Cancer ResearchOncology
2019English

Regulation of PTEN Degradation and NEDD4–1 E3 Ligase Activity by Numb

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2017English

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

Klinicka Onkologie
Oncology
2016English

E3 Ubiquitin Ligase NKLAM Positively Regulates Macrophage Inducible Nitric Oxide Synthase Expression

Immunobiology
AllergyImmunologyHematology
2015English

Sphingosine-1-Phosphate Is a Missing Cofactor for the E3 Ubiquitin Ligase TRAF2

Nature
Multidisciplinary
2010English

The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation

Science
MultidisciplinaryPhilosophy of ScienceHistory
2009English

Catechins and Antitumor Immunity

OncoImmunology
OncologyAllergyImmunology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy